Literature DB >> 11096605

Alpha(1)-Antitrypsin Deficiency.

.   

Abstract

Most of the care of liver disease in alpha(1)-antitrypsin (alpha(1)-AT) deficiency involves supportive management for complications of chronic liver disease including gastrointestinal bleeding, ascites, edema, encephalopathy, coagulation disturbances, spontaneous bacterial peritonitis, and hepatorenal syndrome. Some of these patients will have manifestations of cholestatic injury, including pruritus, hypercholesterolemia, and steatorrhea with fat-soluble vitamin deficiencies. The major challenge for the clinician taking care of these patients is the timing of referral for liver transplantation therapy. Timing of such referral is a relatively straightforward decision in alpha(1)-AT-deficient patients with progressive liver dysfunction. Some patients have nonprogressive or slowly progressing liver disease even after the development of cirrhosis or portal hypertension. Timing of liver transplantation in these patients should not be based simply on the presence of cirrhosis, portal hypertension or mild liver synthetic dysfunction, but rather on the basis of a subjective judgment by the hepatologist, patient, and family that manifestations of liver disease are interfering with overall life functioning.

Entities:  

Year:  2000        PMID: 11096605     DOI: 10.1007/s11938-000-0033-8

Source DB:  PubMed          Journal:  Curr Treat Options Gastroenterol        ISSN: 1092-8472


  44 in total

Review 1.  Antagonists to the rescue.

Authors:  W J Welch; M Howard
Journal:  J Clin Invest       Date:  2000-04       Impact factor: 14.808

Review 2.  Wild-type alpha 1-antitrypsin is in the canonical inhibitory conformation.

Authors:  P R Elliott; J P Abrahams; D A Lomas
Journal:  J Mol Biol       Date:  1998-01-23       Impact factor: 5.469

3.  Cirrhosis associated with alpha-1-antitrypsin deficiency: a previously unrecognized inherited disorder.

Authors:  H L Sharp; R A Bridges; W Krivit; E F Freier
Journal:  J Lab Clin Med       Date:  1969-06

4.  Chemical chaperones mediate increased secretion of mutant alpha 1-antitrypsin (alpha 1-AT) Z: A potential pharmacological strategy for prevention of liver injury and emphysema in alpha 1-AT deficiency.

Authors:  J A Burrows; L K Willis; D H Perlmutter
Journal:  Proc Natl Acad Sci U S A       Date:  2000-02-15       Impact factor: 11.205

5.  A lag in intracellular degradation of mutant alpha 1-antitrypsin correlates with the liver disease phenotype in homozygous PiZZ alpha 1-antitrypsin deficiency.

Authors:  Y Wu; I Whitman; E Molmenti; K Moore; P Hippenmeyer; D H Perlmutter
Journal:  Proc Natl Acad Sci U S A       Date:  1994-09-13       Impact factor: 11.205

6.  Hepatocytes corrected by gene therapy are selected in vivo in a murine model of hereditary tyrosinaemia type I.

Authors:  K Overturf; M Al-Dhalimy; R Tanguay; M Brantly; C N Ou; M Finegold; M Grompe
Journal:  Nat Genet       Date:  1996-03       Impact factor: 38.330

7.  Does previous abdominal surgery alter the outcome of pediatric patients subjected to orthotopic liver transplantation?

Authors:  V Cuervas-Mons; A Rimola; D H Van Thiel; J S Gavaler; R R Schade; T E Starzl
Journal:  Gastroenterology       Date:  1986-04       Impact factor: 22.682

8.  Alpha 1 antitrypsin deficiency: the clinical and physiological features of pulmonary emphysema in subjects homozygous for Pi type Z. A survey by the British Thoracic Association.

Authors:  M J Tobin; P J Cook; D C Hutchison
Journal:  Br J Dis Chest       Date:  1983-01

9.  Survival and FEV1 decline in individuals with severe deficiency of alpha1-antitrypsin. The Alpha-1-Antitrypsin Deficiency Registry Study Group.

Authors: 
Journal:  Am J Respir Crit Care Med       Date:  1998-07       Impact factor: 21.405

10.  Risk of cirrhosis and primary liver cancer in alpha 1-antitrypsin deficiency.

Authors:  S Eriksson; J Carlson; R Velez
Journal:  N Engl J Med       Date:  1986-03-20       Impact factor: 91.245

View more
  1 in total

Review 1.  Gene correction in patient-specific iPSCs for therapy development and disease modeling.

Authors:  Yoon-Young Jang; Zhaohui Ye
Journal:  Hum Genet       Date:  2016-06-02       Impact factor: 4.132

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.